Molecular Endocrinology, Vol 8, 1389-1396, Copyright © 1994 by Endocrine Society

ARTICLES

Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells

G Freiss and F Vignon
INSERM Unit 148 on Hormones and Cancer, Montpellier, France.

Growth of human breast cancer cells is controlled by multiple interacting factors that trigger different intracellular signaling pathways. The nonsteroidal antagonist 4-hydroxytamoxifen (OH-Tam), which acts as an antiestrogen, is also able to inhibit the mitogenic activity of epidermal growth factor (EGF) on hormone-responsive MCF7 cells. To further characterize the mechanism of this antigrowth factor activity, which is accompanied by an increase of high-affinity EGF binding and a drastic decrease in EGF receptor autophosphorylation, we studied the effect of OH-Tam on protein tyrosine phosphatase (PTPase) activity with specific in vitro assays using two different substrates. OH-Tam increased membrane PTPase activity in a time- and dose-dependent fashion whereas cytoplasmic enzyme activity remained unchanged. The increase in PTPase activity was mediated by the estrogen receptor (ER) since it was restricted to ER-positive cells, and the optimal OH-Tam concentration (ED50 = 1 nM) was correlated with the ligand affinity for ER. The increase in enzyme activity was selectively obtained with nuclear receptor ligands (OH-Tam, ICI 164,384) that inhibited growth factor-induced proliferation, whereas other inhibitors of estrogenic responses such as synthetic progestins and antiprogestins had no effect. The time course of stimulation (maximal stimulation at day 4) was concomitant to the loss of EGF mitogenic response. Moreover, addition of a specific PTPase inhibitor (5 microM sodium orthovanadate) to intact cells in culture prevented OH-Tam inhibition of cell proliferation, suggesting that these two events are closely associated.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. Ramaswamy, S. Majumder, S. Roy, K. Ghoshal, H. Kutay, J. Datta, M. Younes, C. L. Shapiro, T. Motiwala, and S. T. Jacob Estrogen-Mediated Suppression of the Gene Encoding Protein Tyrosine Phosphatase PTPRO in Human Breast Cancer: Mechanism and Role in Tamoxifen Sensitivity Mol. Endocrinol., February 1, 2009; 23(2): 176 - 187. [Abstract] [Full Text] [PDF]

				M. Dromard, G. Bompard, M. Glondu-Lassis, C. Puech, D. Chalbos, and G. Freiss The Putative Tumor Suppressor Gene PTPN13/PTPL1 Induces Apoptosis through Insulin Receptor Substrate-1 Dephosphorylation Cancer Res., July 15, 2007; 67(14): 6806 - 6813. [Abstract] [Full Text] [PDF]

				J. Kawagoe, M. Ohmichi, T. Takahashi, C. Ohshima, S. Mabuchi, K. Takahashi, H. Igarashi, A. Mori-Abe, M. Saitoh, B. Du, et al. Raloxifene Inhibits Estrogen-induced Up-regulation of Telomerase Activity in a Human Breast Cancer Cell Line J. Biol. Chem., October 31, 2003; 278(44): 43363 - 43372. [Abstract] [Full Text] [PDF]

				G. Bompard, M. Martin, C. Roy, F. Vignon, and G. Freiss Membrane targeting of protein tyrosine phosphatase PTPL1 through its FERM domain via binding to phosphatidylinositol 4,5-biphosphate J. Cell Sci., June 15, 2003; 116(12): 2519 - 2530. [Abstract] [Full Text] [PDF]

				G. Bompard, C. Puech, C. Prebois, F. Vignon, and G. Freiss Protein-tyrosine Phosphatase PTPL1/FAP-1 Triggers Apoptosis in Human Breast Cancer Cells J. Biol. Chem., November 27, 2002; 277(49): 47861 - 47869. [Abstract] [Full Text] [PDF]

				S. Wakino, U. Kintscher, Z. Liu, S. Kim, F. Yin, M. Ohba, T. Kuroki, A. H. Schonthal, W. A. Hsueh, and R. E. Law Peroxisome Proliferator-activated Receptor gamma Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase Cdelta Pathway in Vascular Smooth Muscle Cells J. Biol. Chem., December 7, 2001; 276(50): 47650 - 47657. [Abstract] [Full Text] [PDF]

				M. Diaz, M. I Bahamonde, H. Lock, F. J Munoz, S. P Hardy, F. Posas, and M. A Valverde Okadaic acid-sensitive activation of Maxi Cl- channels by triphenylethylene antioestrogens in C1300 mouse neuroblastoma cells J. Physiol., October 1, 2001; 536(1): 79 - 88. [Abstract] [Full Text] [PDF]

				A. Chiarenza, P. Lazarovici, L. Lempereur, G. Cantarella, A. Bianchi, and R. Bernardini Tamoxifen Inhibits Nerve Growth Factor-induced Proliferation of the Human Breast Cancerous Cell Line MCF-7 Cancer Res., April 1, 2001; 61(7): 3002 - 3008. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				A. V. Lee, J. G. Jackson, J. L. Gooch, S. G. Hilsenbeck, E. Coronado-Heinsohn, C. K. Osborne, and D. Yee Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo Mol. Endocrinol., May 1, 1999; 13(5): 787 - 796. [Abstract] [Full Text]

				G. Freiss, C. Puech, and F. Vignon Extinction of Insulin-Like Growth Factor-I Mitogenic Signaling by Antiestrogen-Stimulated Fas-Associated Protein Tyrosine Phosphatase-1 in Human Breast Cancer Cells Mol. Endocrinol., April 1, 1998; 12(4): 568 - 579. [Abstract] [Full Text]

				T. Florio, A. Scorziello, S. Thellung, S. Salzano, M. T. Berlingieri, A. Fusco, and G. Schettini Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity Endocrinology, September 1, 1997; 138(9): 3756 - 3763. [Abstract] [Full Text] [PDF]

				T. Florio, A. Scorziello, M. Fattore, V. D'Alto, S. Salzano, G. Rossi, M. T. Berlingieri, A. Fusco, and G. Schettini Somatostatin Inhibits PC Cl3 Thyroid Cell Proliferation through the Modulation of Phosphotyrosine Phosphatase Activity J. Biol. Chem., March 15, 1996; 271(11): 6129 - 6136. [Abstract] [Full Text] [PDF]